Opportunities for Research Participation
Physicians and researchers from the Musculoskeletal Tumors Program at Cincinnati Children's Hospital Medical Center offer clinical research studies for patients with tumors of the bone, soft tissue and spine.
Bone and Soft Tissue Timors
Ewing's Sarcoma
- ADVL0221: A Phase II Study of Trabectedin (ET-743, Yondelis® ) in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Non-rhabdomyosarcomatous Soft Tissue Sarcomas
- ADVL0413: Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias
- ADVL0525: A Phase II Study of Pemetrexed Disodium in Young Patients With Relapsed or Refractory Solid Tumors
- ADVL0612: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors
- ADVL0714: A Phase I Study of VEGF Trap in Children with Refractory Solid Tumors
- ADVL0812: A Phase I Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Pediatric Patients With Relapsed/Refractory Solid Tumors and Leukemia
- AEWS0521: A Randomized Phase II Study of Bevacizumab Combined with Vincristine, Topotecan and Cyclophosphamide in Patients with First Recurrent Ewing Sarcoma
- AEWS07P1: A Pilot Study of Chemotherapy Intensification by adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors
- NCI-07-C-0040: A Phase I Trial of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors
- VITAC: A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Relapsed/Refractory Pediatric Solid Tumors
Osteosarcoma
